AKR1C3 and hepatocellular carcinoma: In summary, we found that AKR1C3 expression was induced obviously in the sorafenib-resistant group and knockdown of AKR1C3 suppressed p-Akt protein levels, ultimately leading to the decrease of HCC cell proliferation.